TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17692951
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ACEI or angiotensin receptor blocker)
Study: 9196934
Drug: Topical dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dorzolamide hydrochloride (3 times a day and 5 times a day)
Study: 9196934
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide (2 weeks)
Study: 8466377
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss intervention (18 months duration, 14 weekly group meetings followed by monthly maintenance sessions)
Study: 3803130
Drug: Graded esophageal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded esophageal balloon distention (10 cc total volume, inflated with 1-cc increments)
Study: 3803130
Drug: Intraesophageal acid
Normalized name: ALCOHOL 80 mL in 100 mL INTRAESOPHAGEAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraesophageal acid perfusion and intravenous edrophonium (80 micrograms/kg)
Study: 29436329
Drug: internet-based cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-based cognitive-behavioural therapy (iCBT) with protocol-driven therapist feedback
Study: 29436329
Drug: internet-based cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-based cognitive-behavioural therapy (iCBT) with feedback on demand
Study: 20533013
Drug: Closed-loop system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop system for propofol administration
Study: 20533013
Drug: Manual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual administration of propofol (Control)
Study: 18606952
Drug: Acid-suppressing agents
Normalized name: BULKING AGENT,APPETITE SUPPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid-suppressing agents
Study: 11549099
Drug: Cilomilast (Ariflo)
Normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilomilast (Ariflo) 15 mg, single and repeat doses, taken before or between meals
Study: 11549099
Drug: Cilomilast (Ariflo)
Normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilomilast (Ariflo) 30 mg, repeat doses, taken after meals
Study: 7908358
Drug: Very-low-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-dose warfarin (1 mg daily for 6 weeks, adjusted to maintain INR of 1.3 to 1.9)
Study: 7908358
Drug: Very-low-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-dose warfarin and Placebo
Study: 363751
Drug: Propoxyphene napsylate
Normalized name: Propoxyphene Napsylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene napsylate (P) 50 mg
Study: 363751
Drug: Fenoprofen calcium
Normalized name: Fenoprofen Calcium
DrugBank: Fenoprofen (DB00573)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenoprofen calcium (F) 600 mg
Study: 363751
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of P and F (P50 + F50)
Study: 363751
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of P and F (P200 + F50)
Study: 363751
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of P and F (P200 + F200)
Study: 363751
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of P and F (P200 + F600)
Study: 26209747
Drug: Weekly ergocalciferol
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly ergocalciferol (50,000 IU) supplementation
Study: 24102055
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (3 cups daily for 14 weeks)
Study: 15508793
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (AA)
Study: 9272339
Drug: DTPwc vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPwc vaccine
Study: 3235234
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of alcohol (for men)
Study: 26269563
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori eradication and treatment with antioxidants
Study: 22762359
Drug: Two small
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two small diameter implants (SDI) ‐ retained overdenture (study group)
Study: 18463993
Drug: Dextromethorphan and
Normalized name: Dextromethorphan and menthol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan and quinidine (DM/Q) 30 mg/30 mg, twice a day
Study: 17063976
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion (CIVS) of lorazepam
Study: 17063976
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of lorazepam
Study: 17063976
Drug: CIVS administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CIVS administration
Study: 9863096
Drug: Fufang Qingdai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufang Qingdai Capsule (FQC)
Study: 31023352
Drug: Adolescent Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescent Cognitive Therapy for Anxiety (ACTA) - six 60-90 min sessions and a booster session
Study: 31023352
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behaviour Therapy (CBT) - eight 2-h sessions and a booster session
Study: 21970061
Drug: Standard vocal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard vocal therapy (Group I, n=33)
Study: 21970061
Drug: Larynx compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Larynx compression vocal therapy (Group II, n=33)
Study: 15536840
Drug: Bionator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bionator therapy (n = 14)
Study: 9301391
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution 25 ml kg‐1 over 30 min (in males)
Study: 9301391
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution 25 ml kg‐1 over 30, 45, and 80 min (in females)
Study: 1376962
Drug: Bunazosin hydrochloride
Normalized name: bunazosin hydrochloride
DrugBank: Bunazosin (DB12230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin hydrochloride (1.5 mg/day)
Study: 1376962
Drug: Bunazosin hydrochloride
Normalized name: bunazosin hydrochloride
DrugBank: Bunazosin (DB12230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin hydrochloride (3.0 mg/day)
Study: 29754811
Drug: Integrated Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Exposure Therapy and Exercise
Study: 27020000
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Bipolar radiofrequency potentiated with infrared light and fractional bipolar radiofrequency)
Study: 25004496
Drug: Psychological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological therapy for 12 weeks
Study: 21988617
Drug: Isoflavone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone (60 mg/day) for 12 months
Study: 21988617
Drug: Isoflavone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone (60 mg/day)
Study: 18030233
Drug: Bravo pH
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bravo pH capsule
Study: 16118573
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) ingestion (4 mL.kg.15 min of 6%)
Study: 10428349
Drug: CDE during
Normalized name: 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
DrugBank: Ellagic acid (DB08846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDE during treatment
Study: 1681365
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated capsules of Ty21a vaccine
Study: 1681365
Drug: Placebo (liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (liquid formulation)
Study: 6345649
Drug: Mepenzolate bromide
Normalized name: Mepenzolate Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepenzolate bromide (MZB) 50 mg, taken 4 times daily for 48 hours
Study: 6345649
Drug: Placebo, taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken 4 times daily for 48 hours
Study: 31575091
Drug: Selenium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (200 µg) and Coenzyme Q10 (200 mg) daily for four years
Study: 24622750
Drug: Indirect infant
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect infant supplementation (400 mg iodine to the mother, placebo to the infant)
Study: 24622750
Drug: Direct infant
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct infant supplementation (100 mg iodine to the infant, placebo to the mother)
Study: 20218995
Drug: 5 IU
Normalized name: Vitamin E 15 IU/0.3 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IU oxytocin bolus and 30 IU infusion
Study: 10357338
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of alkalinized lidocaine with 0 microg phenylephrine (Group 1)
Study: 10357338
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of alkalinized lidocaine with 50 microg phenylephrine (Group 2)
Study: 10357338
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of alkalinized lidocaine with 100 microg phenylephrine (Group 3)
Study: 10357338
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of alkalinized lidocaine with 200 microg phenylephrine (Group 4)
Study: 1672870
Drug: Cyclophosphamide/ACTH treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide/ACTH treatment
Study: 29172994
Drug: Amiloride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (10 mg daily for 5 months)
Study: 23998168
Drug: Potentially inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially inappropriate medications (PIMs) prescribed, including amitriptyline, dextropropoxyphene, quinine, and benzodiazepines.
Study: 23998168
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of inappropriate medication use between those with and without significant depressive symptoms
Study: 21283922
Drug: Fluocinonide 0.1%
Normalized name: FLUOCINONIDE 0.1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocinonide 0.1% cream applied once daily for two weeks
Study: 21283922
Drug: Vehicle applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle applied once daily for two weeks (control)
Study: 17549479
Drug: Gemcitabine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine at standard rate (1,200 mg/m2 over 30 min) + Carboplatin (AUC of 5 over 4 h)
Study: 17549479
Drug: Gemcitabine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine at fixed dose rate (1,200 mg/m2 over 120 min) + Carboplatin (AUC of 5 over 4 h)
Study: 11684971
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural anesthesia combined with light general anesthesia and postoperative intravenous patient-controlled analgesia
Study: 11684971
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia alone with postoperative intravenous patient-controlled analgesia
Study: 9831221
Drug: Mepartricin 40
Normalized name: mepartricin
DrugBank: Mepartricin (DB13633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepartricin 40 mg/daily
Study: 31247504
Drug: Non-opioid agonist
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid agonist treatment (non-OAT)
Study: 25431430
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (primarily individual-based CBT)
Study: 19299776
Drug: Pregabalin 75-300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75-300 mg
Study: 17708607
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) therapy for 6 weeks
Study: 17708607
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) therapy for 3 weeks
Study: 15087291
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g intravenous ascorbic acid (AA)
Study: 8048508
Drug: Chloroquine 250
Normalized name: chloroquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 250 mg
Study: 8048508
Drug: Chloroquine 500
Normalized name: chloroquine 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 500 mg
Study: 182105
Drug: Thyrotropin-releasing factor
Normalized name: Thyrotropin-releasing factor
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thyrotropin-releasing factor (TRF) 43 mg daily for 4 weeks
Study: 24283084
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of spinal plain bupivacaine only (Group B)
Study: 24283084
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg plain bupivacaine with 25 mcg of fentanyl (Group BF)
Study: 21904105
Drug: roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 300 mg
Study: 18798807
Drug: Time taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time taken to return to normal activities after treatment
Study: 16421404
Drug: SonoVue (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue (various doses: 0.3 ml, 0.6 ml, 1.2 ml, 2.4 ml)
Study: 8343473
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C 0.4 mg/ml (0.04%) eye drops, four times a day for 2 weeks post-surgery
Study: 30167757
Drug: Voriconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (400 mg twice on day 1 and 200 mg twice on days 2-5)
Study: 26104432
Drug: Step-down treatment
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down treatment program (short-term day-hospital treatment followed by outpatient combined group and individual psychotherapy)
Study: 22836071
Drug: Pitavastatin 2-4
Normalized name: pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin 2-4 mg/day (PITA, n = 97)
Study: 22836071
Drug: Atorvastatin 10-20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10-20 mg/day (ATOR, n = 92)
Study: 22836071
Drug: Atorvastatin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (n = 67)
Study: 22836071
Drug: Atorvastatin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (n = 20)
Study: 18778758
Drug: Benserazide (inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benserazide (inhibitor of extracerebral dopa decarboxylase)
Study: 18778758
Drug: Carbidopa (inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa (inhibitor of extracerebral dopa decarboxylase)
Study: 16154437
Drug: Hydroxocobalamin (HC)
Normalized name: Hydroxocobalamin
DrugBank: Hydroxocobalamin (DB00200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxocobalamin (HC) 1 mg intravenous weekly for 8 weeks
Study: 16154437
Drug: Cyanocobalamin (CC)
Normalized name: Cyanocobalamin
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyanocobalamin (CC) for 8 weeks
Study: 16154437
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to alternate form (HC or CC)
Study: 10765065
Drug: Finasteride (5α-reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5α-reductase inhibitor)
Study: 10765065
Drug: GI198745 (dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: GI198745 (dual 5α-reductase inhibitor)
Study: 2049752
Drug: POG protocol
Normalized name: Pogostemon cablin top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: POG protocol 8303 (four-drug systemic reinduction: prednisone, vincristine, daunorubicin, and asparaginase; brief intensive consolidation with teniposide and cytarabine; continuation chemotherapy with weekly rotating drug pairs; bilateral testicular radiation (2600 cGy); intrathecal chemoprophylaxis every 4 to 6 weeks)
Study: 6589968
Drug: Cranial radiation
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial radiation and chemotherapy
Study: 6589968
Drug: Longer duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer duration of chemotherapy
Study: 6589968
Drug: Dose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of cranial radiation, concomitant intrathecal methotrexate therapy, and duration of therapy
Study: 27621597
Drug: AZD1981 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1981 1,000 mg bid
Study: 27621597
Drug: AZD1981 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1981 50 mg bid
Study: 27621597
Drug: AZD1981 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1981 400 mg bid
Study: 21051656
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg lasofoxifene
Study: 18052570
Drug: Risperidone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2 to 4 mg/day for 1 year)
Study: 18052570
Drug: Haloperidol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2 to 4 mg/day for 1 year)
Study: 16047123
Drug: Atropine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.01 mg/kg) administered intravenously 3 min prior to treadmill stress
Study: 16047123
Drug: No atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No atropine administered (Control)
Study: 7625665
Drug: Trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent oral poliovirus vaccine (OPV)
Study: 7625665
Drug: Combined diphtheria
Normalized name: tetanus toxoid, combinations with diphtheria toxoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined diphtheria and tetanus toxoids and pertussis vaccine with IPV
Study: 2515822
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (acylated streptokinase, intravenous bolus of 30 units in 4 minutes)
Study: 28295445
Drug: ω‐3 EFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 EFA supplements (1000 mg/day eicosapentaenoic acid + 500 mg/day docosahexaenoic acid)
Study: 25271015
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol esters (4 g) in a high-fat shake
Study: 25271015
Drug: Plant stanol-enriched
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol-enriched margarine (3 g/day)
Study: 18337741
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity administered by the infant's mother (MOM)
Study: 18337741
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity administered by a trained therapist (OT)
Study: 17065618
Drug: Daptomycin 6
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin 6 mg/kg once daily
Study: 17065618
Drug: Daptomycin 6
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin 6 mg/kg once daily plus Gentamicin 1 mg/kg every 8 h
Study: 14998110
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medication and behavioral treatment (Comb)
Study: 11335792
Drug: CsA 10
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA 10 mg/kg
Study: 11335792
Drug: CsA 5
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA 5 mg/kg
Study: 9330586
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (15 mg/kg body weight/day)
Study: 9330586
Drug: Nicotinamide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (25 mg/kg body weight/day)
Study: 7883133
Drug: Fibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic therapy (SK or rtPA)
Study: 18307280
Drug: NSAID treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID treatment (indomethacin or celebrex) for three days preoperatively
Study: 10716466
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (NA) (mean dose 2,250 mg/day)
Study: 10716466
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of gemfibrozil plus NA
Study: 10716466
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy vs. gemfibrozil alone